|
Botella C, Galian JA, Jimenez-Coll V, Fernandez-Gonzalez M, Morales F, Martinez-Gomez G, Gonzalez-Lopez R, Alegria MJ, Moya MR, Martinez-Banaclocha H, Minguela A, Legaz I, Llorente S, Muro M. Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center. Life (Basel). 2024 Nov 16;14(11):1491. doi: 10.3390/life14111491. PubMed PMID: 39598289; PubMed Central PMCID: PMC11595986.
AÑO: 2024; IF: 3.2
|
39598289
|
Hidalgo-Gomez G, Minguela A, Tazon-Vega B, Ribera J, Galian JA, Martinez-Banaclocha H, Garcia-Garay M, Velasco P, Fuster-Soler JL, Armengol G, Ortega M. Clonal heterogeneity and genomic evolution in intrachromosomal amplification of chromosome 21: A case report. Br J Haematol. 2024 Jun;204(6):2512-2515. doi: 10.1111/bjh.19485. Epub 2024 Apr 26. No abstract available. PubMed PMID: 38665061.
AÑO: 2024; IF: 5.1
|
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Martinez Banaclocha H, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia. Clin Transl Oncol. 2024 Jan;26(1):278-287. doi: 10.1007/s12094-023-03251-0. Epub 2023 Jun 27. PubMed PMID: 37368200.
AÑO: 2024; IF: 2.8
|
|
Cuenca I, Botella C, Moya-Quiles MR, Jimenez-Coll V, Galian JA, Martinez-Banaclocha H, Muro-Perez M, Minguela A, Legaz I, Muro M. Genotypic Frequencies of Mutations Associated with Alpha-1 Antitrypsin Deficiency in Unrelated Bone Marrow Donors from the Murcia Region Donor Registry in the Southeast of Spain. Diagnostics (Basel). 2023 Sep 2;13(17):2845. doi: 10.3390/diagnostics13172845. PubMed PMID: 37685383; PubMed Central PMCID: PMC10486455.
AÑO: 2023; IF: 3.0
|
|
Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martinez-Banaclocha H, Hernandez-Rivas JM, Marco-Ayala J, Martinez-Alarcon L, Linares-Latorre L, Garcia-Avila S, Amat-Martinez P, Gonzalez T, Arnan M, Pomares-Marin H, Carreno-Tarragona G, Chen-Liang TH, Herranz MT, Garcia-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrin P, Ferrer-Marin F. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. PubMed PMID: 38118408; PubMed Central PMCID: PMC10772462.
AÑO: 2023; IF: 11.7
|